Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dabur: What to do? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jun 27, 2003

    Dabur: What to do?

    Dabur India Limited has recently decided to demerge its FMCG and Pharma businesses into two separate companies. The company had also reported its FY03 numbers recently. Let's take a look.

    On a consolidated basis, Dabur finished FY03 with a 7% topline growth and over 37% net profit growth. The company's operating profit margins improved by a percent, as sales increased at a faster clip compared to expenses. Softer interest rates too reduced the company's debt servicing costs. All this helped the ayurvedic product major post a healthy bottomline growth in FY03.

    Consolidated Picture
    (Rs m) FY02 FY03 Change
    Net Sales 12,810 13,709 7.0%
    Other Income 120 72 -40.1%
    Expenditure 11,487 12,163 5.9%
    Operating Profit (EBDIT) 1,323 1,546 16.9%
    Operating Profit Margin (%) 10.3% 11.3%  
    Interest 333 261 -21.6%
    Depreciation 287 293 2.2%
    Profit before Tax 823 1,064 29.2%
    Tax (including deffered tax) 136.70 133.30 -2.5%
    Profit after Tax 686 930 35.5%
    Less: Minority Interest -22 -20  
    Net Profit/(Loss) after minority interest 664 911 37.1%
    Net profit margin (%) 5.4% 6.8%  
    Effective tax rate (%) 16.6% 12.5%  
    No. of Shares (eoy) (m) 285.6 285.7  
    Diluted earnings per share* 2.4 3.3  
    P/E ratio   14.7  

    If we look at the performance of its FMCG business (i.e. ayurvedic products, hair oils, oral care, honey, OTC products etc.) and the pharma business (oncology etc.) seperately, we see that almost 85% of Dabur's turnover comes from its FMCG business. This business grew at nearly 5% in FY03, but a grip on operating costs saw operating profits improve by over 21% YoY. This and lower interest outgo helped the FMCG division post over 31% growth at PBT levels. The businesses ROCE doubled to nearly 25% during the year.

    On the other hand, the company's pharma business grew at a faster rate (nearly 13%) during FY03, on a lower base. However, realisations were under pressure, as witnessed by the dip in operating margins. Higher staff and advertising costs led to this pressure on margins. The business however, earns higher operating margins than the FMCG division. It finished FY03 with a 10% growth. The ROCE of the pharma business also improved marginally to over 6% from 5% in FY02.

      FMCG business Pharma business
    (Rs m) FY02 FY03 Change FY02 FY03 Change
    Net Sales 10,003 10,485 4.8% 1,629 1,838 12.8%
    Other Income 94 49 -47.6% 45 34 -24.9%
    Expenditure 9,140 9,438 3.3% 1,426 1,622 13.7%
    Operating Profit (EBDIT) 863 1,047 21.4% 203 216 6.6%
    Operating Profit Margin (%) 8.6% 10.0%   12.5% 11.8%  
    Interest 167 119 -28.7% 72 52 -28.7%
    Depreciation 180 177 -1.4% 30 43 43.7%
    Profit before Tax 609 800 31.2% 146 155 6.7%
    Tax (including deffered tax) 85 7 -91.6% 26 24 -6.6%
    Profit after Tax 525 793 51.1% 120 131 9.6%
    Net profit margin (%) 5.2% 7.6%   7.4% 7.1%  
    Effective tax rate (%) 13.9% 0.9%   17.7% 15.5%  
    No. of Shares (eoy) (m) 285.6 285.7   142.8 142.9  
    Diluted earnings per share* 1.8 2.8   0.8 0.9  

    The ratio for demerger has been set at 1 share of pharma business for every 2 shares held in the original entity. The shareholders will however, receive FMCG business shares in the ratio of 1:1. The move is aimed at bring in more focus to both businesses, as well as to unlock value for shareholders.

    Considering the demerger, even if we give Dabur a valuation of 15 P/E for its FMCG business, the price works out to be around Rs 42 per share and therefore, a market cap to sales of 1.1x. Though this is not a full proof method of arriving at a company's business valuation, it does give some indication of value. This business is the core strength of Dabur currently and going forward it has the capability to grow steadily. However, in the pharma business, the company is at a nascent stage and till date has not shown any remarkable edge in this area. In that light, the value of this business wil not be much. At a conservative 5 P/E, the price of this business will work out to be around Rs 5 per share (taking into consideration the reduction of no. of shares by half).

    At the current price of 48, Dabur (consolidated) trades at a P/E of 14.7x FY03 earnings. In our view, the business is already valued by the markets. Further improvement in valuations will come only after more clarity about management strategy post the demerger. Also, the promoters past track record on bringing in professional managers is not too enthusing.



    Equitymaster requests your view! Post a comment on "Dabur: What to do?". Click here!


    More Views on News

    Marico: Earnings Hit by Lower Volumes and Firming Input Prices (Quarterly Results Update - Detailed)

    Aug 9, 2017

    While GST implementation brought down volumes and profitability in the short run, Marico remains optimistic in the long run.

    Dabur: Premiumisation Efforts to Keep Competition at Bay? (Quarterly Results Update - Detailed)

    May 4, 2016

    Dabur announced its results for the quarter ended March 2016. The company reported a revenue growth of 11% YoY during the quarter, while profits moved up by 17% YoY.

    Dabur: Moving along... (Quarterly Results Update - Detailed)

    Nov 2, 2015

    Dabur announced its results for the quarter ended September 2015. The company reported a revenue growth of 9% YoY during the quarter, while profits moved up by 19% YoY.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)



    Compare Company With Charts